Sarah Gheuens - Feb 10, 2023 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role: Chief Medical Officer
Signature: /s/ William Cook, as attorney-in-fact for Sarah Gheuens
Stock symbol: AGIO
Transactions as of: Feb 10, 2023
Transactions value $: -$21,558
Form type: 4
Date filed: 2/14/2023, 03:07 PM
Previous filing: Dec 28, 2022
Next filing: Mar 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGIO	Common stock	Options Exercise	$0	+2.16K	+13.85%	$0.00	17.8K	Feb 10, 2023	Direct
transaction	AGIO	Common stock	Tax liability	-$21.6K	-758	-4.27%	$28.44	17K	Feb 14, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGIO	Restricted stock units	Options Exercise	$0	-2.16K	-50%	$0.00	2.16K	Feb 10, 2023	Common stock	2.16K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2	The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.